Emerging Tools for Hepatocellular Carcinoma Surveillance

Area of Science:

• Hepatology
• Medical Imaging
• Biomarker Discovery

Background:

• Abdominal ultrasound with alpha-fetoprotein is the standard for hepatocellular carcinoma (HCC) surveillance.
• This method misses over one-third of early-stage HCC cases, highlighting a critical gap in detection.

Purpose of the Study:

• To evaluate emerging imaging modalities and blood-based biomarkers for early-stage HCC surveillance.
• To assess the potential of computed tomography, magnetic resonance imaging, and biomarker panels (GALAD, liquid biopsy) as alternatives or adjuncts to current surveillance.

Main Methods:

• Review of early data on computed tomography and magnetic resonance imaging for HCC detection.
• Analysis of phase II study data for blood-based biomarker panels like GALAD and liquid biopsy.
• Consideration of factors like radiologic capacity, cost, and validation needs for new strategies.

Main Results:

• Emerging imaging modalities show high sensitivity for early HCC but require further evaluation regarding practical implementation and validation in diverse populations.
• Blood-based biomarker panels demonstrate promise in preliminary studies but necessitate large-scale validation through phase III and IV cohort studies.
• Ultrasound with or without alpha-fetoprotein remains the current standard despite its limitations.

Conclusions:

• Current hepatocellular carcinoma (HCC) surveillance strategies have limitations in early detection.
• Emerging imaging and blood-based biomarkers offer potential improvements but require extensive prospective validation.
• Further research is essential to establish reliable and effective early-stage HCC surveillance methods.